Viking Therapeutics, INC Form 4 insider transactions

Viking Therapeutics director Matthew W. Foehr acquired 18,800 stock options on January 2, 2025.

Sarah Kathryn Rouan, a director at Viking Therapeutics, acquired 18,800 stock options on January 2, 2025.

Director Lawson Macartney exercised stock options and sold 2,000 shares of Viking Therapeutics (VKTX) on November 8, 2024.

Viking Therapeutics' CFO, Greg Zante, exercised stock options and sold shares of common stock on October 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Sarah Kathryn Rouan sold 11,000 shares of Viking Therapeutics (VKTX) common stock at $80.89 per share on October 25, 2024, while also exercising options to acquire 11,000 shares at $4.88.

J Matthew Singleton, a director at Viking Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

J Matthew Singleton, a director at Viking Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Viking Therapeutics' CEO, Brian Lian, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Brian Lian, CEO of Viking Therapeutics, exercised stock options and sold 1,000 shares of common stock at $69.90 per share on August 21, 2024, under a pre-arranged Rule 10b5-1 trading plan.

J. Matthew Singleton, a director at Viking Therapeutics, sold 5,700 shares of common stock at an average price of $69.7246, while also exercising options to acquire 5,700 shares at $1.19, all under a pre-arranged trading plan.

Viking Therapeutics' CEO, Brian Lian, sold shares of common stock on August 19, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director J Matthew Singleton exercised stock options and sold shares of Viking Therapeutics (VKTX) under a pre-arranged Rule 10b5-1 trading plan.

J Matthew Singleton, a director at Viking Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Greg Zante, CFO of Viking Therapeutics, reports the acquisition and disposal of company stock following the vesting of performance-based restricted stock units, with subsequent sales to cover tax obligations.

Marianna Mancini, Chief Operating Officer of Viking Therapeutics, reports the acquisition and disposal of company stock following the vesting of performance-based restricted stock units, with subsequent sales to cover tax obligations.

Brian Lian, President & CEO of Viking Therapeutics, reports acquisition and disposal of company stock related to performance restricted stock units (RSUs) and tax obligations.

Chief Financial Officer of Viking Therapeutics, Greg Zante, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Marianna Mancini, Chief Operating Officer of Viking Therapeutics, exercised stock options and sold shares of common stock on May 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Marianna Mancini, Chief Operating Officer of Viking Therapeutics, reports acquisition of shares through vesting of restricted stock units and disposition of shares to cover tax obligations.

Viking Therapeutics' CEO, Brian Lian, reports acquiring shares through performance-based restricted stock units (RSUs) and subsequent disposal to cover tax obligations.

Chief Financial Officer of Viking Therapeutics, Greg Zante, reports acquisition and disposal of company stock related to vesting of performance restricted stock units.

Brian Lian, CEO of Viking Therapeutics, reports the vesting of performance-based restricted stock units and subsequent tax withholding.

Marianna Mancini, COO of Viking Therapeutics, reports the vesting of performance-based restricted stock units and subsequent tax withholding.

Viking Therapeutics' CFO, Greg Zante, reports acquisition and disposal of company stock related to performance-based restricted stock units.